Morgan Stanley

While Moderna grabbed headlines with a 177% jump, its partner Merck recorded its best day since 2009. Morgan Stanley has upgraded its recommendation, highlighting the company's potential beyond its flagship drug, despite the looming patent expiration.

Investment bank Morgan Stanley has reiterated an "overweight" rating and a $300 price target for SpaceX stock, more than double its current price. The bold forecast relies not on rocket launches, but on a $60 billion acquisition deal for an AI startup.